UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib

Clinical pharmacokinetics, 2017-05, Vol.56 (5), p.477-491

2017

Volltextzugriff (PDF)

Model‐Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug Conjugates?

Clinical pharmacology and therapeutics, 2021-11, Vol.110 (5), p.1216-1230

2021

Volltextzugriff (PDF)

Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites

Drug metabolism and disposition, 2015-08, Vol.43 (8), p.1190-1207

2015

Volltextzugriff (PDF)

Clinical Pharmacology Perspectives for Adoptive Cell Therapies in Oncology

Clinical pharmacology and therapeutics, 2022-11, Vol.112 (5), p.968-981

2022

Volltextzugriff (PDF)

Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK

Journal of clinical pharmacology, 2015-09, Vol.55 (9), p.1012-1023

2015

Volltextzugriff (PDF)

Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications

Clinical and translational science, 2022-12, Vol.15 (12), p.2989-2999

2022

Volltextzugriff (PDF)

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

Clinical cancer research, 2010-07, Vol.16 (13), p.3507-3516

2010

Volltextzugriff (PDF)

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer

Cancer chemotherapy and pharmacology, 2017-05, Vol.79 (5), p.923-932

2017

Volltextzugriff (PDF)

Digital twins elucidate critical role of Tscm in clinical persistence of TCR-engineered cell therapy

NPJ systems biology and applications, 2024-01, Vol.10 (1), p.11-12, Article 11

2024

Volltextzugriff (PDF)

Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes

Cancer chemotherapy and pharmacology, 2017-08, Vol.80 (2), p.295-306

2017

Volltextzugriff (PDF)

Drug–Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer

Pharmaceutics, 2022-10, Vol.14 (10), p.2101

2022

Volltextzugriff (PDF)

Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non‐Asian patients with previously untreated diffuse large B‐cell lymphoma in POLARIX

Clinical and translational science, 2023-12, Vol.16 (12), p.2744-2755

2023

Volltextzugriff (PDF)

351 Trends Between Periodontitis and Medial Arterial Calcification in Undiagnosed Type II Diabetes Mellitus

Journal of clinical and translational science, 2023-04, Vol.7 (s1), p.104-104

2023

Volltextzugriff (PDF)

Relative bioavailability and food effect study of an oral suspension of alectinib in healthy volunteers using venipuncture and capillary microsampling

Clinical and translational science, 2023-06, Vol.16 (6), p.1085-1096

2023

Volltextzugriff (PDF)

Liabilities and Risks of Using Cone beam Computed Tomography

The Dental clinics of North America, 2014-07, Vol.58 (3), p.671-685

2014

Volltextzugriff (PDF)

Predicting overall survival from tumor dynamics metrics using parametric statistical and machine learning models: application to patients with RET -altered solid tumors

Frontiers in artificial intelligence, 2024, Vol.7, p.1412865

2024

Volltextzugriff (PDF)

Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study

CPT: pharmacometrics and systems pharmacology, 2024-06, Vol.13 (6), p.1055-1066

2024

Volltextzugriff (PDF)

Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma

CPT: pharmacometrics and systems pharmacology, 2020-01, Vol.9 (1), p.48-59

2020

Volltextzugriff (PDF)

Population pharmacokinetic/pharmacodynamic modeling of tumor growth kinetics in medullary thyroid cancer patients receiving cabozantinib

Anti-cancer drugs, 2016-04, Vol.27 (4), p.328-341

2016

Volltextzugriff (PDF)

Reporting Findings in the Cone Beam Computed Tomography Volume

The Dental clinics of North America, 2014-07, Vol.58 (3), p.687-709

2014

Volltextzugriff (PDF)

Prediction of Human Pharmacokinetics of Antibody–Drug Conjugates From Nonclinical Data

Clinical and translational science, 2019-09, Vol.12 (5), p.534-544

2019

Volltextzugriff (PDF)

Cone Beam Computed Tomography: From Capture to Reporting

The Dental clinics of North America, 2014-07, Vol.58 (3), p.ix-x

2014

Volltextzugriff (PDF)

Interpreting the Cone Beam Data Volume for Occult Pathology

Seminars in orthodontics, 2009-03, Vol.15 (1), p.70-76

Miles, Dale A

2009

Volltextzugriff (PDF)

Clinical Pharmacology Considerations for the “Off‐the‐Shelf” Allogeneic Cell Therapies

Clinical pharmacology and therapeutics, 2024-06, Vol.115 (6), p.1233-1250

2024

Volltextzugriff (PDF)

Occult pathology detected in cone beam data volumes

Alpha Omegan, 2010-12, Vol.103 (4), p.146-150

Miles, Dale A

2010

Volltextzugriff (PDF)

1 – 25 von 313

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(272)
Mit Volltextzugriff
(233)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(313)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib

Model‐Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug Conjugates?

Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites

Clinical Pharmacology Perspectives for Adoptive Cell Therapies in Oncology

Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK

Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer

Digital twins elucidate critical role of Tscm in clinical persistence of TCR-engineered cell therapy

Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes

Drug–Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer

Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non‐Asian patients with previously untreated diffuse large B‐cell lymphoma in POLARIX

351 Trends Between Periodontitis and Medial Arterial Calcification in Undiagnosed Type II Diabetes Mellitus

Relative bioavailability and food effect study of an oral suspension of alectinib in healthy volunteers using venipuncture and capillary microsampling

Liabilities and Risks of Using Cone beam Computed Tomography

Predicting overall survival from tumor dynamics metrics using parametric statistical and machine learning models: application to patients with RET -altered solid tumors

Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study

Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma

Population pharmacokinetic/pharmacodynamic modeling of tumor growth kinetics in medullary thyroid cancer patients receiving cabozantinib

Reporting Findings in the Cone Beam Computed Tomography Volume

Prediction of Human Pharmacokinetics of Antibody–Drug Conjugates From Nonclinical Data

Cone Beam Computed Tomography: From Capture to Reporting

Interpreting the Cone Beam Data Volume for Occult Pathology

Clinical Pharmacology Considerations for the “Off‐the‐Shelf” Allogeneic Cell Therapies

Occult pathology detected in cone beam data volumes

Suchergebnisse filtern